Western and Sumagen to release preliminary results from HIV/AIDS vaccine trials


By Communications Staff
Monday, November 5, 2012
WHAT: Western University and Sumagen Canada will hold a briefing for media and London's research community regarding preliminary results for the first-ever human applied clinical study (SAV CT 01) of the world's only preventative HIV vaccine based on a genetically modified killed whole virus (SAV001-H), which was initiated in March 2012.
Last year, SAV001-H received approval by the United States Food and Drug Administration (FDA) to start human clinical trials.


WHEN: Tuesday, November 6, 2012 at 11 a.m.

WHERE: Siebens Drake Research Institute, Room 217, Western University, London, Ontario

WHO: Dr. Chil-Yong Kang of Western's Schulich School of Medicine & Dentistry and Dr. Dong Joon Kim of Sumagen Co. Ltd.

Media is advised parking is available at Dental Parking Lot (C) and Social Science Lot (J).


MEDIA CONTACT: Jeff Renaud, Senior Media Relations Officer, 519-661-2111, ext. 85165, jrenaud9@uwo.ca














Media Relations team

Keith Marnoch
Director, Media Relations
519-661-2111 x85468

Jeff Renaud
Senior Media Relations Officer
519-661-2111, ext. 85165

Susanna Eayrs

Communications Officer

Kathy Wallis

Media Relations Officer
Medicine & Dentistry Robarts Research Institute
519-661-2111, ext. 81136
kathy.wallis@ schulich.uwo.ca

Douglas Keddy

Research Communications Manager
Research Western
519-661-2111, ext. 87485

Ivan Langrish
Senior Manager, Media Strategy Richard Ivey School of Business


Subscribe to the RSS Feed

RSS Button Media Releases Feed
About this Feed















Western provides the best student experience among Canada's leading research-intensive universities.